【券商聚焦】财通证券维持巨子生物(02367)“增持”评级指其有望实现美妆&医美业务“双重奏”

腾讯自选股07-05

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！金吾财讯 | 财通证券发研报指，巨子生物(02367)发布618战报，双美妆品牌展现高增长势能：可复美：全渠道全周期GMV同比增长超60%，其中天猫/抖音/京东/唯品会同比增长超50%/65%/100%/200%；可丽金：全渠道全周期GMV同比增长超100%，其中天猫/抖音/京东/唯品会同比增长超70%/300%/200%/...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2449657239?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-05 14:33","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2449657239","market":"fut","top_or_hot":-1,"title":"【券商聚焦】财通证券维持巨子生物(02367)“增持”评级 指其有望实现美妆&医美业务“双重奏”","media":"腾讯自选股","content":"<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 金吾财讯 | 财通证券发研报指，巨子生物(02367)发布618战报，双美妆品牌展现高增长势能：可复美：全渠道全周期GMV同比增长超60%，其中天猫/抖音/京东/唯品会同比增长超50%/65%/100%/200%；可丽金：全渠道全周期GMV同比增长超100%，其中天猫/抖音/京东/唯品会同比增长超70%/300%/200%/...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2024-07-05/doc-inccahni7452985.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【券商聚焦】财通证券维持巨子生物(02367)“增持”评级 指其有望实现美妆&医美业务“双重奏”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【券商聚焦】财通证券维持巨子生物(02367)“增持”评级 指其有望实现美妆&医美业务“双重奏”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-05 14:33 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/relnews/cn/2024-07-05/doc-inccahni7452985.shtml><strong>腾讯自选股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 金吾财讯 | 财通证券发研报指，巨子生物(02367)发布618战报，双美妆品牌展现高增长势能：可复美：全渠道全周期GMV同比增长超60%，其中天猫/抖音/京东/唯品会同比增长超50%/65%/100%/200%；可丽金：全渠道全周期GMV同比增长超100%，其中天猫/抖音/京东/唯品会同比增长超70%/300%/200%/...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2024-07-05/doc-inccahni7452985.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-07-05/doc-inccahni7452985.shtml","article_id":"2449657239","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-07-05/doc-inccahni7452985.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2449657239","pubTimestamp":1720161180,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"我们预计2024-2026年收入分别为49.9/64.3/79.5亿元，归母净利润分别为19.9/25.3/31.2亿元，对应PE20/16/13倍，维持“增持”评级。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"601108":"财通证券","02367":"巨子生物"},"translate_title":"[Brokerage Focus] Caitong Securities maintains the \"overweight\" rating of Juzi Biotech (02367), indicating that it is expected to achieve the \"double play\" of beauty & medical beauty business","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601108":1,"02367":1},"content_text":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 金吾财讯 | 财通证券发研报指，巨子生物(02367)发布618战报，双美妆品牌展现高增长势能：可复美：全渠道全周期GMV同比增长超60%，其中天猫/抖音/京东/唯品会同比增长超50%/65%/100%/200%；可丽金：全渠道全周期GMV同比增长超100%，其中天猫/抖音/京东/唯品会同比增长超70%/300%/200%/170%。医美管线落地后巨子预计借助渠道、人群复用等方面快速起量：渠道维度：巨子生物截至2023年底覆盖约4000家医美渠道，其中包括1500家公立+2500家私立，对比来看，锦波生物薇旖美截至2023年底覆盖约2000家机构。人群维度：可复美原有优势产品为敷料及功效型护肤品，主打医美术后修复及特殊状态人群，此部分客群与医美人群高度适配，且对于巨子生物及可复美品牌天然具备强认知、高信任度，可直接复用至医美板块。该行续指，美妆业务持续向好背景下，叠加医美械三产品获批预期，巨子有望实现美妆&医美业务“双重奏”，带动业绩、估值同步提升。我们预计2024-2026年收入分别为49.9/64.3/79.5亿元，归母净利润分别为19.9/25.3/31.2亿元，对应PE20/16/13倍，维持“增持”评级。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449657239"}

【券商聚焦】财通证券维持巨子生物(02367)“增持”评级 指其有望实现美妆&医美业务“双重奏”

精彩评论

【券商聚焦】财通证券维持巨子生物(02367)“增持”评级指其有望实现美妆&医美业务“双重奏”